This page shows the latest Kevzara news and features for those working in and with pharma, biotech and healthcare.
At the same time, some much-trumpeted new launches like cholesterol drug Praluent (alirocumab) and arthritis drug Kevzara (sarilumab) have not delivered on their potential. ... There were some encouraging signs in the third-quarter beyond Dupixent,
There was a glimmer of acceleration for rheumatoid arthritis therapy Kevzara (sarilumab) which climbed 150% to 52m after several quarters of lacklustre performance.
antibody Kevzara (sarilumab) and Pfizer’s JAK inhibitor Xeljanz (tofacitinib), to try to differentiate its drug.
some trumpeted new launches like cholesterol drug Praluent (alirocumab) and arthritis drug Kevzara (sarilumab) have delivered on their potential.
that resulted in commercial products including cholesterol therapy Praluent (alirocumab), Dupixent (dupilumab) for atopic dermatitis and rheumatoid arthritis therapy Kevzara (sarilumab).
Other new products in Sanofi’s portfolio are still not looking too buoyant, particularly Kevzara (sarilumab) for rheumatoid arthritis and high cholesterol therapy Praluent (alirocumab), both of which have struggled to ... Sales of Kevzara in the US
More from news
Approximately 3 fully matching, plus 16 partially matching documents found.
HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....